STEVE KLINE: Open Payments
NPI 1912763137 · CLEBURNE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,828 in 145 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $1,106 · 2025 $1,828
Food & beverage: $1,828
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $392 |
| Alkermes, Inc. | 14 | $368 |
| ABBVIE INC. | 19 | $259 |
| Otsuka America Pharmaceutical, Inc. | 11 | $240 |
| E.R. Squibb & Sons, L.L.C. | 32 | $204 |
| Teva Pharmaceuticals USA, Inc. | 28 | $170 |
| Lundbeck LLC | 6 | $110 |
| Neurocrine BioSciences, Inc. | 2 | $39 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
Products named: CAPLYTA, VRAYLAR, REXULTI, ARISTADA, COBENFY, LYBALVI, UZEDY, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
